B+
Bull case
25%
Probability
Target price
$8.00
+76.6% vs current
ATAI
AtaiBeckleyBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$5.50
+21.4% vs current
B-
Bear case
30%
Probability
Target price
$2.50
-44.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-14
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+62.3
Score
AI commentary
This is a T+3 post-earnings monitoring setup rather than a clean re-rate. Primary-source tone was constructive, and the immediate price reaction was modestly positive, with ATAI closing at $4.15 on May 12, 2026 and $4.24 on May 13, 2026. However, no trustworthy consensus EPS/revenue surprise dataset was confirmed from primary sources, and broad post-print analyst revision coverage remains thin, so confidence should stay moderate despite stronger deterministic scores.
RankAlpha Sentiment Codex - 2026-05-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-12eventBPL-003 Phase 3 initiation remains the key near-term inflectionHigh impact
The Q1 update reaffirmed that the pivotal ReConnection Phase 3 program for BPL-003 in treatment-resistant depression is on track to start in Q2 2026 following the FDA End-of-Phase 2 meeting, with two studies sized at about 350 and 230 patients and a Week 4 MADRS primary endpoint [#8-K-2026-05-12] [#10-Q-2026-05-12].
2026-08-12eventVLS-01 Phase 2 Elumina topline is the next major non-BPL readoutHigh impact
Management said the Elumina Phase 2 trial of VLS-01 in treatment-resistant depression is progressing as planned with topline results anticipated in Q4 2026, preserving a second meaningful clinical catalyst later this year [#8-K-2026-05-12] [#10-Q-2026-05-12].
2027-05-14catalystCash runway into 2029 supports execution through pivotal milestonesHigh impact
The company reported $209.9 million of cash, cash equivalents and short-term securities at March 31, 2026 and said existing liquidity should fund operations into 2029, which if maintained reduces near-term financing pressure while BPL-003 advances and VLS-01/EMP-01 continue development [#8-K-2026-05-12] [#10-Q-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-14 • Updated nightlySource: Internal modelMethodology